← Back to all trials
Recruiting
NCT05015439
Cannabidiol (CBD) in Adults With ASD
Conditions: Autism Spectrum Disorder
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 40
Sponsor: Johns Hopkins University
Location: JHBMC Baltimore Maryland
Summary
There are no FDA approved treatments for use in adults with autism spectrum disorder (ASD), many of whom have distressing anxiety, mood disturbances, sleep problems, and agitation. Some researchers and individuals with ASD have noted that cannabidiol (CBD) is beneficial for those psychiatric problems. This study is to learn more about the effectiveness and safety of CBD in the treatment of psychiatric problems in adults with ASD. The study will last 14 weeks total, during which six weeks participants will receive a pill containing CBD, two weeks where participants will receive no drug/placebo, and six weeks where participants will receive the placebo, an inactive pill. As part of the study, participants will have regular visits and be asked questions about anxiety, challenging behaviors, daily functioning, cognition, and physical symptoms, on standard assessments.
Eligibility Criteria
Inclusion Criteria:
* ASD based on Diagnostic Statistical Manual 5 (DSM-5) criteria
* a significant mood disorder, sleep disturbance, or exhibit agitation, aggression, or other aberrant behavior that is interfering with function and quality of life, as determined by their psychiatric interview
Exclusion Criteria:
* history of alcohol or substance use disorder
* positive urine tetrahydrocannabinol screen at onset of study
* individuals who are pregnant, lactating, or planning pregnancy during or within three months of completing the trial
* individuals with unstable liver disease
* individuals taking medications where CBD interaction might significantly alter drug levels, such as clobazam
Source: ClinicalTrials.gov (NCT05015439). StuddyBuddy aggregates publicly available trial information.